📰 Preclinical Data News
Page 3 - Preclinical Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Preclinical Data. Real-time updates on events, politics, business and more.
March 16, 2023
Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...
November 21, 2022
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - read this article along with other careers information, tips and advice on BioSpace
November 19, 2022
ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with...
November 10, 2022
Investegate announcements from SOTIO Biotech, SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting
October 31, 2022
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022
October 27, 2022
/PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development...
October 20, 2022
Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
September 28, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
September 28, 2022
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
September 7, 2022
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical...